Drug Profile
RA II
Latest Information Update: 26 Aug 2002
Price :
$50
*
At a glance
- Originator Tobishi
- Class Antineoplastics; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Sep 1998 Profile reviewed
- 08 May 1996 Investigation in Cancer in Japan (Unknown route)